التداخل بين بورتيزوميب وبالبوسيكليب

Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use.

Strong CYP3A4 Inhibitors Coadministration with a strong CYP3A4 inhibitor increases the exposure of bortezomib [see Clinical Pharmacology (12.3) ] which may increase the risk of bortezomib toxicities.

Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combination with strong CYP3A4 inhibitors.